SARS-CoV-2 Spike Protein RBD (Delta Plus B.1.617.2.1 Variant) | abx620018

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein Receptor-Binding Domain (RBD) is a recombinant protein expressed in Mammalian cells.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the Spike Protein and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The B.1.617.2.1 (Delta Plus) variant, also known as AY.1, contains the K417N mutation as well as the L452R and T478K mutations in the original B.1.617.2 (Delta) variant. These mutations appear to increase viral infectivity compared with other variants.

Target: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (Delta Plus B.1.617.2.1 Variant)
Target Modification: Lys417Asn, Lys452Arg, Thr478Lys
Modification: Mutation
Origin: Virus
Expression: Recombinant
Host: Mammalian cells
Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.
Conjugation: Unconjugated
Form: Lyophilized
Purity: > 90% (SDS-PAGE)
Reconstitution: Reconstitute in ddH2O to a concentration of 1 mg/ml.
Storage: Store between -20 °C and -80 °C. Avoid repeated freeze/thaw cycles.